Malenka Robert C. 4

What Happened
Robert C. Malenka, a director of MapLight Therapeutics, sold 8,593 shares of MPLT on April 15, 2026. The weighted average sale price was $26.90 per share, resulting in gross proceeds of approximately $231,152. This was a sale (S), not a purchase.

Key Details

• Transaction date: 2026-04-15; Form 4 filed: 2026-04-17 (timely filing).
• Price: weighted average $26.90; individual sale prices ranged from $26.35 to $27.29.
• Shares sold: 8,593; total proceeds ≈ $231,152.
• Shares after transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Sale executed pursuant to a Rule 10b5-1 trading plan adopted Dec 26, 2025.
  • F2: Weighted-average price reported; seller can provide breakdown of shares sold at each price on request.
  • F3: Shares were held by the Robert C. Malenka Living Trust (he is sole trustee with voting/dispositive power).

Context
Sales under Rule 10b5-1 plans are pre-scheduled trading arrangements and are commonly used by insiders to sell shares without regard to short-term company developments; they do not, by themselves, indicate a change in the insider’s view of the company. For retail investors, purchases typically carry more direct bullish signaling than routine, pre-planned sales.